Page 3 - Interventional Cardiovascular Programs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Late-breaking presentation of analysis of SCORED clinical trial data describes significant reduction in cardiovascular death, myocardial infarction and...

21.03.2022 - Late-breaking clinical trial presentation by Deepak L. Bhatt, M.D., M.P.H., will describe new analysis of rates of CV death, myocardial infarction and stroke in the SCORED trialTHE WOODLANDS, Texas, March 21, 2022 (GLOBE NEWSWIRE) - Lexicon ...

New data from a follow-up of more than 30,000 participants without heart failure at enrollment suggests that daily use of aspirin is associated with new onset heart failure.

Idorsia Pharmaceuticals Ltd: Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST Allschwil, Switzerland - June 2 , 2021 Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study "SOS-AMI" to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia's P2Y 12 receptor antagonist, in suspected acute myocardial infarction (AMI). An AMI, or heart attack, is a life-threatening condition that ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute ... Idorsia Pharmaceuticals LtdJune 28, 2021 GMT   Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST Allschwil, Switzerland – June 28, 2021 Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, I...